$LLYB : quick analysis (as of Oct 14, 2026)
What it is: LLYB is not a regular stock. It is a tokenized version of Eli Lilly (NYSE: LLY) on the BNB Smart Chain. Each token is minted 1:1 against a real Eli Lilly share held in a regulated SPV and trades 24/7 on Binance. So its price follows LLY's.
Price: One tracker shows LLYB at about $1,169, up roughly 1% in 24 hours, but volume is thin, at only about $81K a day. Another tracker listed the token near $1,182.
The business behind it:
Lilly raised its 2026 guidance to $82-85 billion in revenue and $35.50-37.00 EPS after Q1.
Q2 revenue grew 36% year over year, driven by Mounjaro, Zepbound and Verzenio.
Analyst targets are bullish, with Barclays at $1,400 and Goldman Sachs at $1,283.
Next catalyst: Q3 earnings are due October 29 before the market opens, with the options market pricing a move of about ±7.4%. Expect volatility around that date.
Risks:
Valuation: a forward P/E near 58 leaves little room for disappointment.
Drug pricing: pricing pressure on GLP-1 drugs and competition from Novo Nordisk remain concerns.
Token risks: thin liquidity, possible price gaps from the real stock, and issuer and regulatory risk. Tokenized stocks may also not be available in all countries, so check that your platform is licensed for you.
Overall view: The trend is bullish and fundamentals are strong, but a lot of good news is already in the price. A holder of LLYB gets mainly LLY exposure plus extra token risks, and the earnings date is the main near-term event to watch.
For the picture, I could not find a reliable live price chart. The images above show Lilly's corporate offices. For a live chart, check LLY on TradingView or Binance's LLYB page.
This is general information, not financial advice. I'm not a financial advisor, so please do your own research before investing.
#CPIWatch #OptimismOPRises19.98% #OpenAIEngineerArrestedOverAllegedOfficeRecording #GoogleReleasesGemini4ArgonAIModel #LedgerAsksSoutheastAsiaHKResellersToHaltSales
What it is: LLYB is not a regular stock. It is a tokenized version of Eli Lilly (NYSE: LLY) on the BNB Smart Chain. Each token is minted 1:1 against a real Eli Lilly share held in a regulated SPV and trades 24/7 on Binance. So its price follows LLY's.
Price: One tracker shows LLYB at about $1,169, up roughly 1% in 24 hours, but volume is thin, at only about $81K a day. Another tracker listed the token near $1,182.
The business behind it:
Lilly raised its 2026 guidance to $82-85 billion in revenue and $35.50-37.00 EPS after Q1.
Q2 revenue grew 36% year over year, driven by Mounjaro, Zepbound and Verzenio.
Analyst targets are bullish, with Barclays at $1,400 and Goldman Sachs at $1,283.
Next catalyst: Q3 earnings are due October 29 before the market opens, with the options market pricing a move of about ±7.4%. Expect volatility around that date.
Risks:
Valuation: a forward P/E near 58 leaves little room for disappointment.
Drug pricing: pricing pressure on GLP-1 drugs and competition from Novo Nordisk remain concerns.
Token risks: thin liquidity, possible price gaps from the real stock, and issuer and regulatory risk. Tokenized stocks may also not be available in all countries, so check that your platform is licensed for you.
Overall view: The trend is bullish and fundamentals are strong, but a lot of good news is already in the price. A holder of LLYB gets mainly LLY exposure plus extra token risks, and the earnings date is the main near-term event to watch.
For the picture, I could not find a reliable live price chart. The images above show Lilly's corporate offices. For a live chart, check LLY on TradingView or Binance's LLYB page.
This is general information, not financial advice. I'm not a financial advisor, so please do your own research before investing.
#CPIWatch #OptimismOPRises19.98% #OpenAIEngineerArrestedOverAllegedOfficeRecording #GoogleReleasesGemini4ArgonAIModel #LedgerAsksSoutheastAsiaHKResellersToHaltSales